KVUE
Kenvue Inc.
NYSE · Consumer Defensive · Household & Personal Products · US
$17.81
−0.34%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$17.80
From 52W high−10.19%
Volume26.62M
Market cap$34.21B
P/E (TTM)20.5x
P/S (TTM)2.2x
Div yield4.67%
Key dataSep 18, 2026
Open
$17.80
From 52W high
−10.19%
Volume
26.62M
Market cap
$34.21B
ValuationView details →
P/E (Fwd)
14.8x
EV/EBITDA
13.1x
P/E (TTM)
20.5x
RSI (14)
36.8
MomentumView details →
1D Return
−0.34%
YTD Return
+3.97%
SummaryUpdated Jun 1, 2026
Kenvue Inc. (NYSE:KVUE) is a consumer health company that emerged as an independent entity in May 2023 following its spin-off from Johnson & Johnson. Founded in 2022 and headquartered in Skillman, New Jersey, Kenvue operates as one of the world's largest pure-play consumer health companies, managing a portfolio of trusted household brands that have been part of families' daily routines for decades. The company went public through an initial public offering in May 2023, marking its transition from being a subsidiary of J&J to a standalone publicly traded corporation focused exclusively on consumer health products.
Similar companies
Latest newsMore news →
Kenvue, the maker of Tylenol, along with pharmacy chains Walgreens, CVS, Walmart and Target, asked the Second U.S. Circuit Court of Appeals to reconsider its July 13, 2026 ruling that revived more than 500 autism-related acetaminophen lawsuits.5d agoKimberly-Clark is preparing concessions to secure EU antitrust approval for its acquisition of Kenvue.6d agoKimberly-Clark is weighing asset sales as the European Union reviews its $40 billion acquisition of Kenvue.6d ago